SIA
LSTA icon

Stancorp Investment Advisers’s Lisata Therapeutics LSTA Stock Holding History

Stancorp Investment Advisers’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$1K Hold
1
– – ﹤0.01% 673
2014
Q4 		$1K Buy
+1
New +$681 ﹤0.01% 666

Other funds holding LSTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Stancorp Investment Advisers's LSTA Position: Q1 2015 in Review

Stancorp Investment Advisers held its Lisata Therapeutics (LSTA) position steady in Q1 2015 at 1 share worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #673.

Stancorp Investment Advisers first reported a position in LSTA in Q4 2014 and has held it in 2 quarters since. 52 funds tracked by Wall St. Rank hold LSTA as of Q1 2015.

  • Stancorp Investment Advisers held 1 share of Lisata Therapeutics worth $1K as of Q1 2015.
  • Stancorp Investment Advisers left its Lisata Therapeutics share count unchanged in Q1 2015.
  • Lisata Therapeutics made up ﹤0.01% of Stancorp Investment Advisers's portfolio in Q1 2015, its #673 holding.
  • Stancorp Investment Advisers first reported a position in Lisata Therapeutics in Q4 2014 and has held it in 2 quarters since.
  • 52 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2015.

Based on Stancorp Investment Advisers's 13F filing for Q1 2015, filed 13 May 2015.